Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab + paclitaxel + capecitabine first-line trial in triple-negative advanced or metastatic breast cancer
2009-016708-21Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Jan 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, paclitaxel and capecitabine in triple-negative breast cancer (TNBC), sponsored by ARCAGY. Primary endpoint: Objective response rate. Started Jan 2010; status: completed.
02
Drugs
bevacizumabpaclitaxelcapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2009-016708-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016708-21.